Temporal Clinical and Laboratory Response to Interleukin-6 Receptor Blockade With Tocilizumab in 89 Hospitalized Patients With COVID-19 Pneumonia.
Darya S FominaMar'yana A LysenkoIrina P BeloglazovaZinaida Yu MutovinaNataliya G PoteshkinaInna V SamsonovaTat'yana S KruglovaAnton A ChernovAlexander V KaraulovPublished in: Pathogens & immunity (2020)
Inflammation and lymphocytopenia are linked to mortality in COVID-19. Inhibition of IL-6 activity by administration of tocilizumab, an anti-IL-6 receptor antibody, is associated with rapid improvement in both CRP and lymphocyte counts and in clinical indices. Controlled clinical trials are needed to confirm the utility of IL-6 blockade in this setting. Additional interventions will be needed for patients requiring mechanical ventilation.
Keyphrases
- mechanical ventilation
- rheumatoid arthritis
- clinical trial
- end stage renal disease
- acute respiratory distress syndrome
- sars cov
- coronavirus disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- juvenile idiopathic arthritis
- respiratory failure
- oxidative stress
- prognostic factors
- rheumatoid arthritis patients
- physical activity
- risk factors
- peritoneal dialysis
- randomized controlled trial
- patient reported outcomes
- coronary artery disease
- type diabetes
- cardiovascular disease
- disease activity